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co-payment groups. Analysis used the auto-regressive integrated moving-average 
model in STATA 9.0. RESULTS: The overall number of outpatient visits signiﬁ cantly 
decreased after policy implementation due to a reduction in the number of patients 
using outpatient facilities, but total costs of care remained unchanged. The policy had 
its greatest impact on the number of visits to regional and local community hospitals 
(secondary), but had no inﬂ uence on those the medical centres (tertiary). Medical 
utilisation in physician clinics (primary) decreased due to an audit of reimbursement 
declarations. Overall, the policy failed to encourage referrals from primary care to 
higher tiers. CONCLUSIONS: Further research needs to explore how patients’ out-
of-pocket payment affects medical utilisation and which forces (not susceptible to co-
payment) act in tertiary facilities. It also needs to investigate, whether the reduction 
in outpatient numbers was due to an affordability barrier to accessing essential care, 
with a potentially negative impact on the region’s health.
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OBJECTIVES: To deter non-essential visits and encourage initial contact in primary
care, Taiwan’s National Health Insurance’s (NHI) implemented a differential co-
payment policy on July 15, 2005. A previous study has examined the impact of this
policy on medical utilization and total cost to NHI using a regional reimbursement 
dataset. This study aimed to explore the impact of this policy on outpatient co-
payment and prescription patterns across different co-payment groups and tiers of 
medical facilities. METHODS: A segmented time-series analysis on regional weekly 
outpatient medical claims (January 2004 to July 2006). Outcome variables for co-
payment and prescription patterns were stratiﬁ ed by tiers of medical facilities and co-
payment groups. Analysis used the auto-regressive integrated moving-average model 
in STATA 9.0. RESULTS: Despite the decrease in outpatient visits, the overall co-
payment to patients increased by 1.2% after policy implementation and also increased
in most medical facilities (4.8% to 17.9%). Number of general prescriptions decreased 
across different medical facilities; the average cost and duration per general prescrip-
tion decreased in medical centers and regional hospitals. The number of continuous 
prescriptions did not change, except for non-signiﬁ cant decreases in medical centers
and regional hospitals. There was an increase in the number of continuous prescrip-
tions dispensed in pharmacies (7.0%). CONCLUSIONS: The police signiﬁ cantly 
increased patients’ out-of-pocket payment for outpatient visits. In response to the 
policy, physicians might prescribe more expensive drugs and extend prescription dura-
tion to help patients get the most beneﬁ t from the co-payment, and physician in
medical centers are more likely to prescribe continuous prescriptions for patients with
stable chronic diseases. Further research needs to identify vulnerable subgroups in 
obtaining necessary treatment, and to explore the impacts of cost-saving strategies on 
patients’ quality of medical care.
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Kaisaeng N, Zhang JX
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: We sought to evaluate the impact of pharmacy cost-containment policy 
actions by state Medicaid programs on cost-related underuse of medicine, controlling
for concurrent non-pharmacy cost-containment policy actions and socio-environmen-
tal differences among states. METHODS: We used the data from the 2003 Community
Tracking Study (CTS) household survey, and linked them with the census demographic 
data and the cost containment policy actions based upon 50 States Surveys on state 
Medicaid spending growth and cost containment policy actions by the Kaiser Family
Foundation in 2003. A cross-sectional study was performed to evaluate the impact of 
policy actions, by comparing Medicaid beneﬁ ciaries to non-Medicaid-pharmacy-cost-
containment-action-eligible residents. The outcome measures included: patients do not 
receive needed medical care, patients cannot afford needed prescriptions, patients
postpone needed medical care, and patients worry about the medical care cost. The 
outcomes were analyzed using logit model, with prior authorization, generic drugs
required, copayment method, step therapy of fail-ﬁ rst requirement, limit on number 
of prescriptions and number of reﬁ lls per month, preferred drug list, over the counter
coverage, and prescription drug payment practices (payment and purchasing policies) 
as predictors. Additionally, non-pharmacy cost-containment policy actions, patients’
demographics and states’ socio-environmental variables were controlled. RESULTS:
On average, each state has implemented 6.5% pharmacy cost containment policy
actions in 2003. Only the worrying about costs was statistically signiﬁ cantly associated
with individual pharmacy cost-containment policy action; however, such signiﬁ cance
disappeared after other concurrent pharmacy cost-containment policy actions were
controlled for. When the total number of pharmacy cost-containment policy actions
was entered in the regression instead of individual policy action, each incremental 
policy action was associated with 14% increase in odds ratio for unmet medical needs
(p  0.003), and 5% increase in odds ratio for postponing medical needs (p  0.02). 
CONCLUSIONS: There was variable impact of pharmacy cost-containment policy
actions when assessed concurrently, and collectively.
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OBJECTIVES: Although cost-effectiveness analysis allows efﬁ cient decisions about the 
use of existing technologies (static efﬁ ciency) it has been argued that it will disincen-
tivise the development of innovative technologies (dynamic efﬁ ciency). These concerns
have also been raised about the report by the UK Ofﬁ ce of Fair Trading which recom-
mended that the price of pharmaceuticals should be based on their cost-effectiveness. 
We aim to establish whether decisions based on cost-effectiveness necessarily under-
mine incentives for the development of pharmaceuticals. METHODS: The arguments
put forward as to why cost-effectiveness decisions might undermine incentives for
innovation are examined and are used to consider the implications of the type of 
value-based pricing which has been proposed in the UK. RESULTS: The argument 
depends on whether the purpose of health care is to improve population health or to 
maximise welfare (consumer and producer surplus). If it is the former, then achieving
static and dynamic efﬁ ciency requires a clear and predictable signal of value (cost-
effectiveness). The private sector can then choose to invest in developments which it 
believes will be cost-effective and provide a satisfactory return on investment. Manu-
facturers should be allowed to appropriate some share of the surplus (monopoly rent) 
to incentivise investment in R&D. However, they should not take it all. The public 
sector subsidises research and development in many ways. Therefore, even if society
was unconcerned about who beneﬁ ts from innovation it would not be efﬁ cient to
allow full appropriation. In other markets where innovation is protected, society 
simply offers monopoly rent during patent protection but does not allow full appro-
priation by, for example, facilitating perfect price discrimination. CONCLUSIONS:
The argument that decisions about the use and price of a technology based on cost-
effectiveness will undermine the incentives for R&D is misplaced if the objective is to 
improve population health given a ﬁ xed budget constraint.
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OBJECTIVES: The Orphan Drug Act (ODA) was developed in 1983 to stimulate new
drug development to treat rare diseases. The purpose of this analysis was to review
the drug development with orphan drug status and to describe utilization of orphan 
drugs in the Medicaid program. METHODS: A literature review about orphan drug 
approvals was conducted through search engine like PubMed, as well as government
and industry Internet websites. Nationwide Medicaid pharmacy data extracted from
the Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 
regarding quarterly prescriptions, reimbursements, and cost per prescription for
selected orphan drugs. Based on utilization patterns, two categories of orphan drugs
were studied, including traditional ones with little use (like antizole, fabrazyme, 
respigam, myozyme, and panhematin) and non-traditional ones with wide usages (like
paclitaxel, epoetin alfa, and imatinib mesylate). RESULTS: Since 1983, over 1700
drugs have been designated as having orphan status and 325 drugs have marketing
approval to treat orphan diseases, focusing on oncology, metabolic and endocrine 
disorders, and hematology. From Medicaid pharmacy data, there was very little use
for antizole, respigam, myozyme, and other traditional orphan drugs, such as fabra-
zyme from 15 in 2003 to the peak of 375 in 2006. By contrast, non-traditional orphan 
drug like epoetin alfa prescriptions increased from 17,282 in 1991 to the peak of 
824,485 in 2005, and imatinib mesylate prescriptions increased from 3,877 in 2001
to the peak of 20,323 in 2005. Fabrazyme cost per prescription started with $22,367
in 2003 and decreased to $5,558 in 2006. Other expensive orphan drugs included
myozyme, panhematin, imatinib mesylate, and ritumximab ranging from $3,000 to 
$10,000 per prescription. CONCLUSIONS: ODA has made a signiﬁ cant impact on
drug development for rare diseases. Non-traditional orphan drugs with dramatic 
increased utilization and spending were observed, which might require safety surveil-
lance and appropriate utilization review.
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OBJECTIVES: The pharmaceutical industry serves societal needs by bringing innova-
tive products and therapies to market. However, innovation does not guarantee 
market longevity. Consequently, some products will be evaluated and considered for 
market discontinuation. The purpose of this study was to identify drug market dis-
continuations, provide reasons for discontinuation, and characterize discontinued 
products by application type. METHODS: Data were derived from the FDA databases 
“Approved Drug Products” and the “Approved Drug Products with Therapeutic 
Equivalence Evaluations,” Federal Register, and Medline. Market discontinuations 
were classiﬁ ed by approval types (New Drug Application -NDA and Abbreviated New 
Drug Application-ANDA) and by reasons for discontinuation (safety, efﬁ cacy and 
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ﬁ nancial reasons). Biological licenses and tentative approvals were excluded from 
analysis. Results were obtained using descriptive statistics and chi-squared tests. 
RESULTS: FDA databases contained a total of 2093 drug product and combination 
approvals between February 1939 and December 2008. Of those products, 42.3% 
had generic competition. A total of 595 (28.4%) drug products were discontinued
during the study period. Discontinued products included 37.2% of the brand products 
and 15.6% of the generic products (p  0.001). Safety was the reason for discontinu-
ation for 59 drug products, which represented 2.8% of the approved drugs and 
accounted for 9.9 % of the product discontinuations. Databases contained 23,931
approvals, including 8,174 NDAs and 15,757 ANDAs. Discontinued applications
accounted for 42.3% of all applications, and included 43.9% of the NDAs and 41.8% 
of the ANDAs approved during the study period. CONCLUSIONS: One-third of the
drugs approved by the FDA and more than 40% of the applications were discontinued 
during the study period. Safety discontinuations constituted a small, but signiﬁ cant, 
percentage of the discontinuations. Other reasons for discontinuation included
product obsolescence and ﬁ nancial reasons. Drug discontinuations pose signiﬁ cant 
implications for research, product development, and determining societal needs for
innovative pharmaceutical products.
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OBJECTIVES: To assess newspaper coverage of ‘off-label drug and medical device
use’ over the period of 1990 to 2008, explore key themes of discussion, and identify
the tone of coverage. METHODS: The ProQuest media database was accessed for 
news articles published from January 1990 to July 2008 from the top six selling 
national newspapers. From the initial 1066 articles retrieved, 153 were selected for 
analysis based on inclusion and exclusion criteria. Main outcome measures were the 
number of articles published; type of themes covered; headline, content and overall
article tone (positive, negative or neutral); speciﬁ c concerns and beneﬁ ts discussed 
with off-label use; and primary individual interviewed for the article. RESULTS:
The articles published on off-label drug use steadily increased over the period of 
study. The primary themes discussed were concerns over safety and efﬁ cacy (44.4%), 
beneﬁ ts of off-label prescribing (26.8%), general announcements by the FDA (9.2%), 
insurance coverage issues (6.5%), and combination of beneﬁ ts and concerns (12.4%).
The tone of headlines was mainly neutral (60.1%) although one quarter was negative 
(25.5%). Within the articles, however, the overall tone was judged more negative for
off-label use (39.9% of articles). The majority of articles (58.8%) used clinicians as 
the primary commenter with other articles using government representatives (11.1%)
patients and patient advocates (7.8%), and drug company spokespeople (5.9%) 
for comments. Inter-coder reliability were in the acceptable ranges, Cohen’s kappa 
(0.7–0.85) and percentage agreement (80%). CONCLUSIONS: Off-label drug use
has gotten increasing media attention over the years. An understanding of the media 
coverage enables us to get a better understanding of public perception on this issue.
Overall, coverage has been more negative than positive with articles expressing more 
concerns than beneﬁ ts. Moreover, off-label prescribing is an important and a sensitive 
issue and hence, media sources should be urged to present this topic with a neutral
approach.
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OBJECTIVES: To quantify medication wastage for Lipid Lowering Agents, Antihy-
pertensive Therapy, and Proton Pump Inhibitors. METHODS: This study focused on 
drug waste for new to therapy patients. The therapy classes under consideration were 
Lipid Lowering Agents (N  12,978), Antihypertensive Therapy (N  15,975), and
Proton Pump Inhibitors (N  14,365). The claims came from an aggregate of a segment
of Medco Health Solutions clients. We calculated overall percentage of patients that 
wasted medication as well as percentage of days supply that they wasted. To focus on
avoidable waste, we deﬁ ned a wastage event as a switch within therapeutic class. We 
also stratiﬁ ed the days supply into 3 categories less than or equal to 30 days, between 
30 and 90 days, and greater than or equal to 90 days. RESULTS: For Lipid Lowering
Therapy: Overall 1.5% of patients had wastage of 0.7% days supplied. Stratiﬁ cation
by days: days   30 1.2% of patients and 0.4% of days, 30  days 90 2.4% of 
patients and 0.9% of days, days   90 2.9% patients and 1.2% of days. For Anti-
hypertensive Therapy: 6.2% patients had wastage of 2% days supplied. Stratiﬁ cation
by days: days   30 6.3% of patients and 2.1% of days, 30  days 90 5.1% of 
patients and 2.1% of days, days   90 5.2% patients and 2% of days. For PPI’s: 
1.9% patients had wastage of 0.7% days supplied. Stratiﬁ cation by days: days   30 
1.9% patients and 0.7% of days, 30  days 90 0.9% of patients and 0.3% of days, 
days   90 1.8% patients and 0.7% of days. CONCLUSIONS: The drug wastage 
for the above therapies is very small and so is the difference between the wastage for
30 day supply vs. 90 or greater day supply. Therefore drug wastage should not be a 
major concern when choosing different plan designs.
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OBJECTIVES: To analyze medication costs and utilization in hospice care using PBM 
claims data from hospices in Ohio. METHODS: A retrospective analysis was con-
ducted using claims from January 1 through December 31 2007 from ﬁ ve hospices in
Ohio. The data contains information regarding prescription medication utilization and 
their costs. Descriptive analyses were conducted to identify ten therapeutic drug classes 
with the most frequent utilization rates and largest percentage of expenditures. 
Further, descriptive analyses were conducted to examine the differences in prescription
drug count and total cost by therapeutic class and by drug name for each hospice and
for all hospices combined. RESULTS: The average number of admissions in each 
hospice for the calendar year 2007 was 527, 50.6% being male. The drug expenditures 
for each hospice averaged $498,301 per year. Approximately 1020 different medica-
tions under 246 therapeutic classes were found to be utilized in the ﬁ ve hospices. The 
most frequently utilized therapeutic class of medications, based on prescription medi-
cation count included analgesic-narcotics (14.9%) followed by laxatives-cathartics
(7.2%), and anti-anxiety drugs (6.7%). Therapeutic classes contributing to the major-
ity of drug expenditures included opioid analgesics (16.5%), SSRIs (4.7%), and anti-
anxiety drugs (4.5%). Medications whose frequency of use contribute to signiﬁ cant
expense include morphine sulfate (5.3% – utilization & 4.4% – expenses), and loraz-
epam (4.4% & 3.1%.). Individual drug products not frequently utilized, although
signiﬁ cantly contribute to expenses include fentanyl (3.5%) and low molecular weight 
heparin products(3.1%). CONCLUSIONS: Although the overall costs for hospice care 
to Medicare and patients is less as compared to the costs incurred by conventional 
non-palliative focused care, the cost for medications in a hospice program is signiﬁ -
cant. Hospices should place emphasis on the utilization of cost effective drugs that
can be used among terminally ill patients to provide a high level of quality care with
ﬁ scal responsibility.
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OBJECTIVES: We characterized a sub-population of Premera BlueCross members on 
multiple chronic medications and evaluated an educational, mail-based program 
designed to address the safety of multiple prescription users. METHODS: Polyphar-
macy members were selected based on early 2005 chronic prescription claims. Selected
members were   19 years of age and were continuously eligible for both prescription
and medical beneﬁ ts during the evaluation period (August 2004–January 2007).
Pharmacy and medical claims were analyzed to compare monthly medication frequen-
cies and safety-related medical events (emergency room (ER) visits and hospitaliza-
tions) between the pre- and post-intervention periods. Generalized linear mixed 
modeling was used to test for time-period differences in prescriptions. The top ICD-9 
codes for ER visits and hospitalizations, as well as the most frequently prescribed 
medications were reported. Polypharmacy members were grouped into medication-
count categories and prescription and medical event proﬁ les were developed.
RESULTS: For the ﬁ nal analysis sample of N  12,962 members (65% female; mean
age: 53 years), a comparison of the two periods indicated an increase of approximately 
0.5 in mean monthly medication counts during the post-period (6.3 vs. 6.8 prescrip-
tions; p  0.0001). GLMM applied to monthly medications indicated signiﬁ cant dif-
ferences in the mean number of monthly medications at period start as well as in the
slope of monthly medication trends during the periods. ER visits and hospitalizations 
(safety-related events) were reduced by roughly 1% in the post-period (23% to 22%, 
13% to 12%, respectively; both p  0.0001). Reductions in events were observed 
across medication-count categories. Medications for hypertension, high LDL choles-
terol, and diabetes were among the most frequently prescribed in both periods. 
CONCLUSIONS: This evaluation demonstrates the need for more studies and focus 
on sub-populations of health challenged members. Well-designed, controlled studies
could further test the effects of medical/pharmacist intervention strategies for members
taking multiple medications.
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PRESCRIBING IN ELDERLY OUTPATIENTS: A COHORT STUDY
Abouzaid S1, Del Canale S2, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2LHU Parma, Montechiarugolo, Parma, 
Italy
OBJECTIVES: To establish explicit criteria for potentially inappropriate medication 
prescribing (PIP) for the elderly and assess the prevalence of and factors associated 
with PIP among elderly residents in the Local Health Unit (LHU) of Parma, Italy 
according to the developed criteria. METHODS: A nine-member expert panel was 
convened to develop a list of inappropriate medications reﬂ ecting the Italian pres-
cribing habits. Using the 2002 Beers criteria as a framework, consensus through a 
two-round Delphi method was reached to classify the identiﬁ ed 23 inappropriate 
medications into three categories: 17 medications to be always avoided, 3 medications 
rarely appropriate, and 3 medications with some indications but often misused. A 
retrospective cohort study using the 2006 Parma LHU automated outpatient prescrip-
tions database was conducted. The cohort comprised 91,741 individuals q65 years 
